Highly regioselective biotransformation of ginsenoside Rb2 into compound Y and compound K by β-glycosidase purified from Armillaria mellea mycelia

被引:36
作者
Kim, Min-Ji [1 ]
Upadhyaya, Jitendra [1 ]
Yoon, Min-Sun [2 ]
Ryu, Nam Soo [2 ]
Song, Young Eun [3 ]
Park, Hee-Won [4 ]
Kim, Young-Hoi [1 ]
Kim, Myung-Kon [1 ]
机构
[1] Chonbuk Natl Univ, Dept Food Sci & Technol, 567 Baekje Daero, Jeonju 54896, South Korea
[2] Chonbuk Natl Univ, Dept Food Sci & Biotechnol, Iksan, South Korea
[3] Jeollabuk Do Agr Res & Extens Serv, Iksan, South Korea
[4] Korea Ginseng Corp, Korea Ginseng Corp Res Inst, Daejeon, South Korea
关键词
Armillaria mellea; beta-glycosidase; biotransformation; compound Y; ginsenoside Rb2; RARE GINSENOSIDES; PANAX-GINSENG; BIOCONVERSION; GLUCOSIDASE; SAPONINS; RC; PHARMACOKINETICS; BIOAVAILABILITY; PROTOPANAXADIOL; TRANSFORMATION;
D O I
10.1016/j.jgr.2017.07.001
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: The biological activities of ginseng saponins (ginsenosides) are associated with type, number, and position of sugar moieties linked to aglycone skeletons. Deglycosylated minor ginsenosides are known to be more biologically active than major ginsenosides. Accordingly, the deglycosylation of major ginsenosides can provide the multibioactive effects of ginsenosides. The purpose of this study was to transform ginsenoside Rb2, one of the protopanaxadiol-type major ginsenosides, into minor ginsenosides using beta-glycosidase (BG-1) purified from Armillaria mellea mycelium. Methods: Ginsenoside Rb2 was hydrolyzed by using BG-1; the hydrolytic properties of Rb2 by BG-1 were also characterized. In addition, the influence of reaction conditions such as reaction time, pH, and temperature, and transformation pathways of Rb2, Rd, F2, compound O (C-O), and C-Y by treatment with BG-1 were investigated. Results: BG-1 first hydrolyzes 3-O-outer beta-D-glucoside of Rb2, then 3-O-beta-D-glucoside of C-O into C-Y. C-Y was gradually converted into C-K with a prolonged reaction time, but the pathway of Rb2 -> Rd -> F2 -> C-K was not observed. The optimum reaction conditions for C-Y and C-K formation from Rb2 by BG-1 were pH 4.0-4.5, temperature 45-60 degrees C, and reaction time 72-96 h. Conclusion: beta-Glycosidase purified from A. mellea mycelium can be efficiently used to transform Rb2 into C-Y and C-K. To our best knowledge, this is the first result of transformation from Rb2 into C-Y and C-K by basidiomycete mushroom enzyme. (C) 2017 The Korean Society of Ginseng, Published by Elsevier Korea LLC.
引用
收藏
页码:504 / 511
页数:8
相关论文
共 34 条
[1]   Ginseng pharmacology - Multiple constituents and multiple actions [J].
Attele, AS ;
Wu, JA ;
Yuan, CS .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1685-1693
[2]  
Bae EA, 2000, BIOL PHARM BULL, V23, P1481, DOI 10.1248/bpb.23.1481
[3]  
CHEN Y, 1987, CHEM PHARM BULL, V35, P1653
[4]   Transformation of ginsenosides Rb2 and Rc from Panax ginseng by food microorganisms [J].
Chi, H ;
Kim, DH ;
Ji, GE .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (11) :2102-2105
[5]  
Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043-4526(08)00401-4
[6]   Efficient biotransformation for preparation of pharmaceutically active ginsenoside Compound K by Penicillium oxalicum sp 68 [J].
Gao, Juan ;
Xu, Wenjing ;
Fang, Qiang ;
Liang, Fei ;
Jin, Rutian ;
Wu, Di ;
Tai, Guihua ;
Zhou, Yifa .
ANNALS OF MICROBIOLOGY, 2013, 63 (01) :139-149
[7]   DEGRADATION OF GINSENG SAPONINS UNDER MILD ACIDIC CONDITIONS [J].
HAN, BH ;
PARK, MH ;
HAN, YN ;
WOO, LK ;
SANKAWA, U ;
YAHARA, S ;
TANAKA, O .
PLANTA MEDICA, 1982, 44 (03) :146-149
[8]   Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid [J].
Hasegawa, H .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (02) :153-157
[9]   Biotransformation of ginsenoside Rd in the ginseng extraction residue by fermentation with lingzhi (Ganoderma lucidum) [J].
Hsu, Bo Yang ;
Lu, Ting Jang ;
Chen, Chia Hui ;
Wang, Shing Jung ;
Hwang, Lucy Sun .
FOOD CHEMISTRY, 2013, 141 (04) :4186-4193
[10]  
Jin F., 2012, INT J BIOMED PHARM S, V6, P33